PhRMA Backs AstraZeneca In Bid For Fed. Circ. Redo
A split Federal Circuit decision giving Mylan a second chance to invalidate AstraZeneca inhaler patents "sows confusion" about how numbers should be read in patents, the Pharmaceutical Research and Manufacturers of...To view the full article, register now.
Already a subscriber? Click here to view full article